Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of C$1.40 and traded as high as C$1.40. Oncolytics Biotech shares last traded at C$1.40, with a volume of 181,909 shares trading hands.
Analyst Ratings Changes
Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.
Get Our Latest Stock Analysis on Oncolytics Biotech
Oncolytics Biotech Stock Performance
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
- Five stocks we like better than Oncolytics Biotech
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- What is an Earnings Surprise?
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- Stock Sentiment Analysis: How it Works
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
